Table 3.
Clinical characteristics of the study samples (N; percentages in parentheses)
| German reference men [n = 988] | German PC patients with scheduled radiotherapy [n = 121] | German PC patients with scheduled radical prostatectomy [n = 371] | p-values for differences between German RT and RP patients | Canadian PC patients with scheduled radiotherapy [n = 66] | Canadian PC patients with scheduled radical prostatectomy [n = 68] | p-values for differences between Canadian RT and RP patients | |
|---|---|---|---|---|---|---|---|
| D'Amico Risk Score | Not | p < 0.001# | |||||
| Low | 39 (32.2) | 24 (6.5) | |||||
| Intermediate | 39 (32.2) | 46 (12.4) | |||||
| High | applicable | 43 (35.5) | 301 (81.1) | - | - | ||
| Gleason score (pre-treatment) Mean ± SD |
Not applicable | 6.13 ± 1.33 | 6.35 ± 1.21 | p < 0.096* | - | - | |
| Highest recorded pre-treatment PSA [ng/ml] (mean ± SD) | Not applicable | 13.7 ± 17.3 | 10.2 ± 17.9 | p = 0.066* | 14.3 ± 14.6 | 8.81 ± 6.9 | p = 0.006* |
Gleason score and D'Amico risk score were not assessed in the Canadian study
* analysis of variance # chi-square tests